To include your compound in the COVID-19 Resource Center, submit it here.

New BIO leader McMurry-Heath to focus on patients and innovation

Michelle McMurry-Heath to lead BIO in new direction

BIO is looking to its new CEO and President, Michelle McMurry-Heath, to serve as a new face and voice for the industry, and to refocus the organization on patients and on creating the innovations they need.

McMurry-Heath is taking on the role at a time when the COVID-19 pandemic has focused the world’s attention on the biopharma industry, and the public is hungry for leaders who can speak about science and medicine with credibility, empathy and authenticity.

The crisis has already demonstrated that scientists like NIAID Director Anthony Fauci can become national heroes, and thought leaders like former FDA Commissioner Scott Gottlieb can earn trust that eludes elected government officials.

If McMurry-Heath can achieve this kind of stature she could shape the national conversation about biomedical innovation during and beyond the pandemic.

McMurry-Heath speaks in terms that aren’t usually part of the public dialogue about drug development and policy, and has talked widely about focusing on “social justice” issues. In a BioCentury This Week -- Special Report podcast, she spelled out that this involves emphasizing the potential of scientific breakthroughs to reduce social inequities.

“The thing that is really going

Read the full 1903 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE